

# Chronic kidney disease in ARPKD

Dr Sarah Ledermann, GOSH

ARPKD family information and support day 28<sup>th</sup> June 2014

# Measuring kidney function

Creatinine (umol/l) : derived from muscle creatine phosphate and filtered by kidney

Glomerular filtration rate (GFR): can measure or estimate (mls/min/1.73m<sup>2</sup>)

$$\text{Estimated GFR} = \frac{\text{Height (cm)} \times k}{\text{pCr}} \quad (\text{Schwarz formula})$$

*In the malnourished infant / child formula may overestimate the true GFR*

# Chronic Kidney Disease classification

Stage	Description	GFR	Action
1	Kidney damage with normal GFR	$\geq 90$	Diagnosis/ treatment Slow progression Treat co morbidity Reduce CVS risk
2	Mild decrease in GFR	60-89	Estimate progression
3	Moderate decrease in GFR	A 45-59	Evaluate and treat complications
B		30-44	
4	Severe decrease in GFR	15-29	Prepare for renal replacement therapy
5	Renal failure	$\leq 15$	Start RRT

# CKD - management issues in ARPKD

- ❑ Growth and nutrition
- ❑ *Blood pressure control*
- ❑ Metabolic disturbance - acidosis and *salt wasting*
- ❑ CKD – Mineral and bone disorder
- ❑ Anaemia
- ❑ Infection ie urinary tract / liver
- ❑ Delaying progression – BP / proteinuria/ hydration / acidosis / hyperphosphateamia
- ❑ Neurodevelopment / psychosocial issues
- ❑ Preparation for dialysis/ transplantation

# Nutrition in CKD

Poor appetite / nausea / vomiting

Inadequate dietary intake

Malnutrition / Cachexia

Growth failure

Adverse psychosocial  
outcome

# Why children with CKD/ ARPKD feed poorly

- Altered appetite regulation / gastrointestinal motility/microcolon*
- Respiratory compromise*
  
- Abnormal taste sensation
- Polydipsia associated with polyuria
- Disturbed feeding history
- Infections
- Multiple medications
  
- Other co-morbidities*

# Methods of infant feeding – oral

Encourage oral feeding- breast if possible or normal infant formula

<2 yr - whey dominant infant formula

>2 yr – whole protein based drinks / feed

- ❑ Manipulation of feeds: ↑ concentration +/- carbohydrate supplements; ↓ volume
  
- ❑ Medications
  - Prokinetic agents ie domperidone
  - H<sub>2</sub>- receptor antagonists ie ranitidine
  - Proton pump inhibitors ie lansoprazole
  - Anti-histamine ie alimemazine
  
- ❑ Advice to prevent development of food aversive behaviour

# Why tube feed?

- In first 12 weeks of life maximal post natal growth
  - If wt/ht static for 2/52 ↓ 1 centile
  - If wt/ht static for 4/52 ↓ 2 centiles
  
- After 26 weeks: 3 weeks ↓ 1 centile  
40 weeks: 4 weeks ↓ 1 centile

Failure to achieve expected growth despite dietary manipulation / medication should prompt instigation of tube feeding

*EARLY INTERVENTION IS IMPORTANT*



# Methods of tube feeding

❑ Nasogastric tube

❑ Gastrostomy

- percutaneous endoscopic gastrostomy (PEG)
- radiologically inserted gastrostomy (RIG)
- gastrostomy button ( open/laparoscopic) +/- fundoplication

Feeds given as

- ❖ Bolus feeds / top-up feeds ( gravity or pump)
- ❖ Overnight continuous feed with day time boluses
- ❖ Overnight feeds only
- ❖ Continuous feeds

# Salt and BP in ARPKD

- Salt losses from distal dilated collecting ducts  
*Need salt supplementation as low blood sodium (hyponatraemia)*
- Hypertension as pressure of cysts on juxtaglomerular cells  
*Need anti hypertensive medications*
- Reduced urinary concentrating ability with polyuria and polydipsia  
*Need rapid rehydration / free access to H<sub>2</sub>O*
- As kidney function worsens kidney cannot get rid of water /salt  
*Need to decrease salt / H<sub>2</sub>O intake or become overloaded / need dialysis*

# Acidosis in CKD

Increased bicarbonate (alkali) losses  
Reduced acid excretion


*Maintain  $t\text{Co}_2 \geq 22 \text{ mmol/l}$  with sodium bicarbonate : 1-2mmol/kg/day*

- Improve nitrogen balance
- Optimise growth
- Prevent bone demineralisation
- Prevent hyperkalaemia
- Preserve renal function

# CKD – Mineral and Bone Disorder

- Abnormal calcium, phosphate, parathyroid hormone and Vit D metabolism
- Abnormal bone turnover, mineralisation and growth
- Calcification of the cardiovascular system and soft tissue

# CKD-Mineral bone disease



Persistent stimulation  $\longrightarrow$  Hyperplasia  $\longrightarrow$  Tertiary HPT

# Management of CKD-MBD

## Aims

- Maintain i-PTH normal range
- Maintain phosphate at < 50th centile for age
- Maintain normal total and ionised calcium for age
- Achieve normal bone metabolism
- Prevent vascular calcification

## Methods

- Adequate supply of vitamin D
- Adequate calcium intake
- Correct acidosis
- Phosphate control by dietary restriction / phosphate binders
- Active vitamin D metabolite – lowest possible dose

*Early screening / treatment to prevent parathyroid hyperplasia*

# Phosphate binders

- ❑ Calcium carbonate (soluble 250mg), calcichew, adcal)
- ❑ Calcium acetate (phosex, renacet)
- ❑ *Sevelamer hydrochloride (renagel) / sevelamer carbonate (renvelar)*

*Match prescription to dietary intake*

*Monitor calcium / phosphate*

# Vitamin D in CKD- MBD

- Ergocalciferol (D<sub>2</sub>) or Colecalciferol (D<sub>3</sub>) supplement

Introduce activated vitamin D when increased PTH with controlled phosphate and meeting RNI for Vit D from feeds or supplement

- 1 alpha - hydroxycalciferol (alfacalcidol)  
Dose: 0.02 - 0.1 µg/kg
- 1,25 - dihydroxycalciferol (calcitriol)



# Anaemia in CKD

Due to erythropoietin deficiency/ resistance and iron dysregulation

## UK Adult and Paediatric Renal Standards 2000

Age	Hb g/dl	Evaluate anaemia
■ <6months	11.5 ( 9.5 - 13.5)	<9.5
■ 6m-2years	12.5 (10.5 -13.5)	<10.5
■ thereafter	13.5 (11.5 -15.5)	<11.5

# Treatment of anaemia in CKD

- Ensure adequate available iron availability and iron stores

transferrin saturation (Fe/TIBC x 100) > 20%

ferritin 100 - 500 mcg/l

- Exclude other causes of anaemia i.e. blood loss, inflammation (raised CRP), folate or B12 deficiency, haemolysis, haemoglobinopathy

- Erythrocyte stimulating agents ( ESA's)

***Erythropoietin  $\beta$***       ***100 - 300 u/kg/week sc***

***Darbepoietin  $\alpha$***       ***0.75mcg/kg/every 2-4 weeks sc***

# Treatment of anaemia

## Benefits of treatment with ESA's

- Increased energy / activity
- Improved appetite / growth
- Improved cardiac function as anaemia is a haemodynamic risk factor for cardiomyopathy (LVH)
- Reduced need for blood transfusions with risk of HLA sensitisation and infections

# Dialysis and renal transplantation in ARPKD

- Peritoneal dialysis – likely to need to remove one or both kidneys
- Haemodialysis – usually will have kidneys removed
- Kidney transplant - pre-emptive ie no dialysis  
- after a period of dialysis

*Live-related or deceased donor transplant*

*Combined kidney/ liver transplant*